Comera Life Sciences Holdings, Inc.
Index- P/E- EPS (ttm)-1.36 Insider Own22.30% Shs Outstand19.09M Perf Week-10.56%
Market Cap36.10M Forward P/E- EPS next Y- Insider Trans3.15% Shs Float9.41M Perf Month-9.04%
Income-9.00M PEG- EPS next Q- Inst Own26.00% Short Float6.42% Perf Quarter-40.15%
Sales0.20M P/S180.48 EPS this Y242.00% Inst Trans-56.44% Short Ratio0.21 Perf Half Y-84.20%
Book/sh-0.22 P/B- EPS next Y- ROA-11.00% Target Price- Perf Year-83.98%
Cash/sh0.22 P/C7.37 EPS next 5Y- ROE-12.20% 52W Range1.11 - 15.30 Perf YTD-84.11%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-89.48% Beta-
Dividend %- Quick Ratio2.10 Sales past 5Y- Gross Margin59.10% 52W Low45.05% ATR0.46
Employees9 Current Ratio2.10 Sales Q/Q8.60% Oper. Margin- RSI (14)43.69 Volatility20.52% 24.47%
OptionableNo Debt/Eq- EPS Q/Q-453.90% Profit Margin- Rel Volume0.07 Prev Close1.89
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume2.88M Price1.61
Recom- SMA20-24.63% SMA50-34.09% SMA200-76.24% Volume206,855 Change-14.81%
Aug-31-22 04:15PM
Aug-11-22 08:00AM
Aug-10-22 04:15PM
Jun-22-22 08:00AM
Jun-16-22 08:00AM
Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore. Its SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions. The company is advancing its primary product programs, CLS-001, a preclinical stage biobetter for Crohn's and Ulcerative Colitis disease, and CLS-002, a preclinical stage biobetter for various oncology indications. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cherington Charles10% OwnerSep 29Buy1.8717,90033,477604,930Sep 30 04:04 PM
Cherington Charles10% OwnerSep 27Buy1.6912,00020,221587,030Sep 29 04:02 PM
Sherblom JamesDirectorSep 12Buy2.0350,000101,500371,163Sep 12 05:25 PM
Hackman Jeffrey S.See RemarksSep 09Buy2.0647,60098,05647,600Sep 12 05:23 PM
Campbell Michael GerardEVP & CFOSep 08Buy2.0725,00051,75025,000Sep 12 05:25 PM